Jacobus Pharma wins USFDA approval for Ruzurgi to treat rare autoimmune disorder
The drug, Ruzurgi, was approved for use in patients aged between 6 and 17, the FDA said Lambert-Eaton myasthenic syndrome, which affects about three people per million worldwide, affects the connection between nerves and muscles, disrupting the ability of nerve cells to send signals to muscle cells.
New Delhi: Jacobus Pharmaceutical Co Inc on Monday won U.S. approval for the first drug to treat children with Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder.
Read Also: Alembic Pharma gets USFDA approval for Olopatadine Hydrochloride Ophthalmic Solution
The drug, Ruzurgi, was approved for use in patients aged between 6 and 17, the FDA said Lambert-Eaton myasthenic syndrome, which affects about three people per million worldwide, affects the connection between nerves and muscles, disrupting the ability of nerve cells to send signals to muscle cells.
The treatment currently available has been approved only for adults.
Read Also: Sanofi wins USFDA approval to sell dengue vaccine Dengvaxia in parts of US
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd